Genedrive’s Genetic Test for Newborns Rolled Out Across NHS Scotland

An announcement from Genedrive ( (GB:GDR) ) is now available.

Genedrive plc has announced the national rollout of its Genedrive® MT-RNR1 ID Kit across NHS Scotland, a move that aims to reduce the risk of deafness in newborns requiring antibiotic treatment in neonatal intensive care units. This initiative, supported by NHS Greater Glasgow and Clyde, is expected to significantly enhance patient care by allowing for rapid genetic testing and informed treatment decisions, ultimately improving health outcomes and quality of life for newborns and their families.

The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.

Spark’s Take on GB:GDR Stock

According to Spark, TipRanks’ AI Analyst, GB:GDR is a Neutral.

Genedrive is navigating profitability challenges despite strong revenue growth and a solid balance sheet. Technical analysis indicates bearish momentum, while valuation metrics are unappealing due to lack of profitability. However, recent corporate developments are promising, potentially enhancing market positioning and future prospects.

To see Spark’s full report on GB:GDR stock, click here.

More about Genedrive

Genedrive plc is a UK-based pharmacogenetic testing company specializing in the development and commercialization of rapid, low-cost, and easy-to-use point-of-care pharmacogenetic platforms. These platforms aid clinicians in making informed decisions about medicine choices and dosages, particularly in emergency healthcare settings. The company’s flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, are designed to improve patient outcomes by providing quick genetic information to guide treatment decisions.

Average Trading Volume: 56,628,444

Technical Sentiment Signal: Sell

Current Market Cap: £9.78M

See more data about GDR stock on TipRanks’ Stock Analysis page.